TH Share Price

Open 2.97 Change Price %
High 3.02 1 Day 0.01 0.34
Low 2.95 1 Week -0.10 -3.26
Close 2.97 1 Month -0.34 -10.27
Volume 39300 1 Year 1.45 95.39
52 Week High 3.74
52 Week Low 1.26
TH Important Levels
Resistance 2 3.03
Resistance 1 3.01
Pivot 2.98
Support 1 2.93
Support 2 2.91
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
YRI 4.04 3.86%
SC 60.83 -0.44%
PRE 0.64 0.00%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
TPL 0.02 100.00%
TPL 0.02 100.00%
ANX 0.06 20.00%
ANX 0.06 20.00%
MBA 0.57 11.76%
MBA 0.57 11.76%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
RN 0.10 -16.67%
RN 0.10 -16.67%
DNT 0.10 -16.67%
KOR 0.61 -11.59%
KOR 0.61 -11.59%
ONC 0.20 -9.09%
ONC 0.20 -9.09%
XTC 10.20 -6.93%
DEJ 0.14 -6.67%
More..

Theratechnologies Inc (TSE: TH)

TH Technical Analysis 1.5
As on 2nd Dec 2016 TH Share Price closed @ 2.97 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.37 & Sell for SHORT-TERM with Stoploss of 3.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
TH Target for December
1st Target up-side 3.44
2nd Target up-side 3.72
3rd Target up-side 4
1st Target down-side 2.64
2nd Target down-side 2.36
3rd Target down-side 2.08
TH Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.theratech.com
TH Address
TH
2310 Alfred-Nobel Boulevard
Montr, QC H4S 2B4
Canada
Phone: 514-336-7800
Fax: 514-331-9691
Interactive Technical Analysis Chart Theratechnologies Inc ( TH TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Theratechnologies Inc
TH Business Profile
Theratechnologies Inc., a biopharmaceutical company, develops and commercializes therapeutic peptide products. The company’s lead product is EGRIFTA (tesamorelin for injection), an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in the United States. It also focuses on commercializing EGRIFTA in Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, Thailand, and certain central Asian countries. Theratechnologies Inc. also has TH1173, a second-generation GRF peptide that has completed preclinical studies in its product pipeline. The company was founded in 1993 and is headquartered in Montréal, Canada.